Biotech entity
pharma is the sole category represented across all 1 tracked stories. Argus Research is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Merck & Company, Inc., all published on August 22, 2026.
Last mentioned: 1d ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Argus Research is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Merck & Company, Inc., all published on August 22, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 3 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Merck & Company, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Argus raises Merck price target
Argus lifts its Merck target from $130 to $145 with a Buy rating, citing pipeline depth and clinical progress.
Merck discloses Evaxion stake
Merck reports holding 1,214,126 shares of Evaxion A/S in a regulatory filing.
Merck exercises EVX-B3 option
Merck decides to in-license Evaxion's discovery-stage AI-derived vaccine candidate EVX-B3 against an undisclosed bacterial pathogen.
Merck's option to in-license Evaxion's EVX-B3 vaccine candidate, combined with a 1.21 million-share stake, provides early validation for the biotech's AI antigen discovery platform. For biotech investors, the deal is a discovery-stage bet with long clinical timelines.
Merck & Company, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
